770 related articles for article (PubMed ID: 26225674)
1. Is Surgical Staging Necessary for Patients with Low-risk Endometrial Cancer? A Retrospective Clinical Analysis.
Kokcu A; Kurtoglu E; Celik H; Kefeli M; Tosun M; Onal M
Asian Pac J Cancer Prev; 2015; 16(13):5331-5. PubMed ID: 26225674
[TBL] [Abstract][Full Text] [Related]
2. Influence of body mass index on clinicopathologic features, surgical morbidity and outcome in patients with endometrial cancer.
Akbayır O; Corbacıoglu Esmer A; Numanoglu C; Cılesız Goksedef BP; Akca A; Bakır LV; Kuru O
Arch Gynecol Obstet; 2012 Nov; 286(5):1269-76. PubMed ID: 22729137
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological risk factors for pelvic lymph node metastasis in clinical early-stage endometrioid endometrial adenocarcinoma.
Zhang C; Wang C; Feng W
Int J Gynecol Cancer; 2012 Oct; 22(8):1373-7. PubMed ID: 22932266
[TBL] [Abstract][Full Text] [Related]
4. Lymphovascular space invasion is highly associated with lymph node metastasis and recurrence in endometrial cancer.
Hahn HS; Lee IH; Kim TJ; Lee KH; Shim JU; Kim JW; Lim KT
Aust N Z J Obstet Gynaecol; 2013 Jun; 53(3):293-7. PubMed ID: 23600915
[TBL] [Abstract][Full Text] [Related]
5. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.
AlHilli MM; Podratz KC; Dowdy SC; Bakkum-Gamez JN; Weaver AL; McGree ME; Keeney GL; Cliby WA; Mariani A
Gynecol Oncol; 2013 Oct; 131(1):103-8. PubMed ID: 23845691
[TBL] [Abstract][Full Text] [Related]
6. Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysis.
Papathemelis T; Hassas D; Gerken M; Klinkhammer-Schalke M; Scharl A; Lux MP; Beckmann MW; Scharl S
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2019-2027. PubMed ID: 30039227
[TBL] [Abstract][Full Text] [Related]
7. Comparison of myometrial invasion and tumor free distance from uterine serosa in endometrial cancer.
Ozbilen O; Sakarya DK; Bezircioglu I; Kasap B; Yetimalar H; Yigit S
Asian Pac J Cancer Prev; 2015; 16(2):519-22. PubMed ID: 25684481
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
[TBL] [Abstract][Full Text] [Related]
9. Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.
Kim TH; Kim HS; Kim TJ; Chang SJ; Kim DY; Ryu SY; Kim BG; Kim YT; Bae DS; Ryu HS; Nam JH
Gynecol Oncol; 2016 Jun; 141(3):440-446. PubMed ID: 27020700
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
11. Survival advantage of lymphadenectomy in endometrial cancer.
Eggemann H; Ignatov T; Kaiser K; Burger E; Costa SD; Ignatov A
J Cancer Res Clin Oncol; 2016 May; 142(5):1051-60. PubMed ID: 26746654
[TBL] [Abstract][Full Text] [Related]
12. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial.
Eltabbakh GH; Piver MS; Hempling RE; Shin KH
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):373-80. PubMed ID: 9226326
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for paraaortic lymph node metastasis in endometrial cancer.
Sari ME; Yalcin İ; Sahin H; Meydanli MM; Gungor T
Int J Clin Oncol; 2017 Oct; 22(5):937-944. PubMed ID: 28523533
[TBL] [Abstract][Full Text] [Related]
14. Lymphovascular space involvement is the sole independent predictor of lymph node metastasis in clinical early stage endometrial cancer.
Vaizoglu F; Yuce K; Salman MC; Basaran D; Calis P; Ozgul N; Usubutun A
Arch Gynecol Obstet; 2013 Dec; 288(6):1391-7. PubMed ID: 23764931
[TBL] [Abstract][Full Text] [Related]
15. Lymphovascular space invasion and the treatment of stage I endometrioid endometrial cancer.
van der Putten LJ; Geels YP; Ezendam NP; van der Putten HW; Snijders MP; van de Poll-Franse LV; Pijnenborg JM
Int J Gynecol Cancer; 2015 Jan; 25(1):75-80. PubMed ID: 25356534
[TBL] [Abstract][Full Text] [Related]
16. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
Klopp AH; Jhingran A; Ramondetta L; Lu K; Gershenson DM; Eifel PJ
Gynecol Oncol; 2009 Oct; 115(1):6-11. PubMed ID: 19632709
[TBL] [Abstract][Full Text] [Related]
17. Three-Year Recurrence-Free Survival in Patients With a Very Low Risk of Endometrial Cancer Who Did Not Undergo Lymph Node Dissection (Tree Retro): A Korean Multicenter Study.
Kim M; Choi C; Kim K; Lim MC; Park JY; Hong JH; Lee M; Paek J; Seoung J; Lee S; Lee TS
Int J Gynecol Cancer; 2018 Jul; 28(6):1123-1129. PubMed ID: 29664841
[TBL] [Abstract][Full Text] [Related]
18. Nomogram to Predict Risk of Lymph Node Metastases in Patients With Endometrioid Endometrial Cancer.
Pollom EL; Conklin CM; von Eyben R; Folkins AK; Kidd EA
Int J Gynecol Pathol; 2016 Sep; 35(5):395-401. PubMed ID: 26598977
[TBL] [Abstract][Full Text] [Related]
19. Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
Sueoka K; Umayahara K; Abe A; Usami T; Yamamoto A; Nomura H; Matoda M; Okamoto S; Omatsu K; Kondo E; Kato K; Takeshima N
Int J Gynecol Cancer; 2015 Jan; 25(1):81-6. PubMed ID: 25347094
[TBL] [Abstract][Full Text] [Related]
20. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
